Business
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM, an internationally-recognized hepatologist, and authority
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical trials SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor (IFNAR) agonist designed to selectively activate the interferon-α pathway within the liver and offer the convenience of oral dosing. Interferon-α is a subcutaneous injectable therapy approved for HBV that has demonstrated functional cure of HBV in some HBV patients, though its tolerability profile significantly limits its use. By focusing exposure on the liver, Assembly Bio’s investigational IFNAR agonist program aims to engage interferon-α’s validated antiviral and immune modulatory mechanisms while reducing systemic exposure to improve tolerability. The program will feature presentations, discussion, and Q&A with the following speakers: Edward J. Gane, MBCHB, MD, FRACP, MNZM, Professor of Medicine at the University of Auckland, New Zealand; Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital The Role of Interferon in HBV Cure John McHutchison, AO, MD, Chief Executive Officer and President at Assembly Bio Leveraging Assembly Bio’s Expertise in Small Molecules and Viral Hepatitis to Expand the Company’s Portfolio William Delaney, PhD, Chief Scientific Officer at Assembly Bio Assembly Bio’s Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program The live webcast will be available on the Events & Presentations page in the Investors section of Assembly Bio’s website and a replay will be accessible following the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. About Assembly BiosciencesAssembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 296 million people liv...